This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

AMRI Hires Vijay Kumar Batra As Managing Director, AMRI India

ALBANY, N.Y., Jan. 10, 2014 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) today announced the appointment of Vijay Kumar Batra, to the position of Managing Director, AMRI India, effective January 2, 2014. Mr. Batra will report to Steve Hagen, Ph.D., Senior Vice President of Manufacturing and Pharmaceuticals.

"Mr. Batra brings a wealth of experience in the Active Pharmaceutical Ingredients (APIs) and intermediates business and he also brings a leadership acumen that helps AMRI continue our plan for growth in the Indian and world markets," said Dr. Hagen. "We are excited to have Vijay on our leadership team. He has a strong record of leading business growth in the area of API and intermediates and is highly respected by those who have worked with him and the businesses he has led."

Before coming to AMRI, Mr. Batra held a number of executive roles with Teva Pharmaceuticals Industries Ltd. since 2003. Most recently, he was Vice Chairman and Managing Director, Teva API India, responsible for research and development and manufacturing of API's and advanced intermediates for the global market. The facilities overseen by Mr. Batra had strong compliance records and achieved U.S. Food and Drug Administration and other international certifications. Mr. Batra also served as Chairman of Teva API China during his most recent tenure. Prior to these roles, Mr. Batra was President and Director of JK Drugs and Pharmaceuticals and Advisor at JK Pharmachem Ltd. He also held other roles with Ranbaxy, Kinetics Technology India Ltd., and Synthetics and Chemicals Ltd. Mr. Batra was also responsible for Drug Product Manufacturing and was Vice Chairman of Tevapharm India Pvt. Ltd. during his last few years.

Mr. Batra earned a Bachelor's degree in Technology from the Indian Institute of Technology and is an alumnus of the Wharton Business School's Senior Executive Development program.

About AMRIAlbany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 22 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers with informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

SOURCE AMRI

Stock quotes in this article: AMRI 
Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,262.56 +89.32 0.55%
S&P 500 1,842.98 +12.37 0.68%
NASDAQ 4,034.1610 +11.4670 0.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs